Our bodies chronic conditions are interconnected by deficiencies and traceable failures within their structures, this can be monitored and managed by AI through phone apps - but once we get the data how do we treat these chronic conditions? Our public health systems are antiquated and complex, and premium advice can come with a waiting list of months when diagnosis is then an urgency due to deterioration of any condition. We need new set of tools beyond wound care dressings and over extended consultants. Diabetes and its complications will have cost the NHS £100k by the time you have read this web page. There are 450,000 people in the UK at high risk of Diabetic Foot Ulcers, of this group, 7,000 diabetics annually will require amputations due to ulcers and, up to 70% of diabetics die within 5 years of having an amputation*. In the UK, GrafMed could immediately up to 5,000 lives and the NHS £12.9m/yr in identified ‘high risk’ diabetic patients. This will potentially continue to get worse throughout the World as diets based upon processed foods become more widespread and with them, the complications and health dangers they present. Current health diagnosis can be segmented in approach, whereby multiply appointments to see specialist consultants who identify a number of health failures and will require multiple appointments and treatments to correct all the issues involved, this involves huge resource and cost for the NHS. Future healthcare will be more wholistic and will provide the individual with a more comprehensive set of data. This growing gap between early diagnosis and fragmented public health systems will require a new level of medical innovation that bridges the gap between digital awareness and actual physical treatment. For example, 80% of at risk diabetics do not wear any preventative orthotic footwear. *NICE guidance to practice (Diabetics), 2017
GrafMed was formed in 2016, after identifying a new approach to wound care. We formed as a group to look into the benefits of new materials and how it could be used even more extensively in the health sector. The reliance on healthcare professionals has always been key to effective wound care treatment, clinical pathways are followed based upon decades of experience, however, new technologies in the digital sector have now begun to challenge this status quo. GrafMed spoke to surgeons and NHS management and medical device developers before we began the task of developing the right technology. When we had gathered this information, we approached a UK Catapult Centre to look into formulation of a prototype materials to demonstrate these qualities. As each work package progressed, we began to adapt the next phase of that development, undertaking commercial material considerations and opening the door again to the clinical side of Diabetic foot ulcers, via Accelerator courses at BioCity in Alderley Park. As we continue to develop technical innovation, building on our granted patent, we now have the opportunity to go for further investment as a continuation of these new and exciting technologies. The opportunities they may bring are not just for Diabetes but as a smart materials bridge between digital healthcare interface and advanced wound care products.